Patents by Inventor Gary Witherell
Gary Witherell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8012465Abstract: Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced toxicity and adverse side effects compared to high dose IL-2 therapy.Type: GrantFiled: July 28, 2009Date of Patent: September 6, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Laurence Elias, Gary Witherell
-
Patent number: 7432047Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: October 4, 2006Date of Patent: October 7, 2008Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 7285383Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: August 1, 2005Date of Patent: October 23, 2007Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20070218470Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: October 4, 2006Publication date: September 20, 2007Inventors: Vincent Miles, Michael Mathews, Michael Katze, Julia Watson, Gary Witherell
-
Publication number: 20070014765Abstract: Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced toxicity and adverse side effects compared to high dose IL-2 therapy.Type: ApplicationFiled: January 27, 2006Publication date: January 18, 2007Applicant: Chiron CorporationInventors: Laurence Elias, Gary Witherell
-
Patent number: 7045284Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: June 14, 2004Date of Patent: May 16, 2006Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20050265975Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: August 1, 2005Publication date: December 1, 2005Inventors: Vincent Miles, Michael Mathews, Michael Katze, Julia Watson, Gary Witherell
-
Publication number: 20040254140Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: June 14, 2004Publication date: December 16, 2004Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6824976Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: November 28, 2000Date of Patent: November 30, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6777179Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 27, 2002Date of Patent: August 17, 2004Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6667152Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 22, 2002Date of Patent: December 23, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6623961Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 28, 2002Date of Patent: September 23, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20030144226Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 27, 2002Publication date: July 31, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6579674Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: March 28, 2002Date of Patent: June 17, 2003Assignee: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20020165194Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 28, 2002Publication date: November 7, 2002Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20020160976Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 22, 2002Publication date: October 31, 2002Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Publication number: 20020160977Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: ApplicationFiled: March 28, 2002Publication date: October 31, 2002Applicant: Rigel Pharmaceuticals, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell
-
Patent number: 6156496Abstract: Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component reduces the level of translation of an RNA of the virus.Type: GrantFiled: September 8, 1997Date of Patent: December 5, 2000Assignee: Ribogene, Inc.Inventors: Vincent J. Miles, Michael B. Mathews, Michael G. Katze, Julia C. Watson, Gary Witherell